Best Grants for HIV / AIDS in Montana

Nonprofit 501(c)(3) organizations in Montana working on HIV/AIDS research, education, treatment, or related community services can apply for Foster Foundation support. Funding may also cover broader medical care, human services, education, and community engagement programs that serve underserved and disadvantaged residents, including children, women, and seniors in the Pacific Northwest region.

Nonprofit organizations and fiscally sponsored groups in Montana and the broader Northwest serving LGBTQ+ communities through health, wellness, HIV/AIDS prevention, education, or community-building programs can seek funding of approximately US $10,000. Grants from Pride Foundation prioritize BIPOC- and TGNC-led, grassroots, and rural efforts advancing equity and justice for LGBTQ+ people.

Research institutions and other eligible organizations conducting substance use and HIV-related studies in Montana can access funding through the National Institutes of Health to run pilot and feasibility projects. These grants support developing and testing prevention, treatment, recovery, and implementation interventions for substance use disorders and HIV in affected populations, including work that engages community and policy stakeholders.

Research institutions and early-career investigators conducting HIV/AIDS research on chronic conditions, coinfections, and comorbidities can seek funding in Montana and nationwide. US Dept. of Health & Human Services: National Institutes of Health supports pioneering HIV prevention and treatment studies, especially for pediatric and maternal populations, encouraging innovative approaches from fields like mathematics, engineering, computer science, and AI.

Montana HIV / AIDS researchers and research institutions can access funding through the US Dept. of Health & Human Services: National Institutes of Health to study how HIV immunotherapies affect central nervous system outcomes. This R21/R33 opportunity offers up to US $2,000,000 for biphasic projects examining CNS HIV persistence, neurotoxicity, and long-term neurologic and cognitive outcomes.

Montana HIV/AIDS research organizations and clinical trial units can access funding through the National Institutes of Health to support prevention and treatment studies. This opportunity backs Clinical Trials Units that provide scientific expertise, manage clinical research sites, and conduct randomized controlled trials and implementation research on HIV and HIV-associated diseases, including international studies that benefit U.S. populations.

Research institutions and data centers working on HIV prevention, treatment, and implementation science, including those in Montana, can apply for clinical trials network Statistical and Data Management Center roles from the National Institutes of Health. Funding supports leadership in trial design, data collection and monitoring, analysis, regulatory compliance, and harmonized, innovative HIV data practices.

Research institutions and clinical trial organizations in Montana working on HIV/AIDS prevention, treatment, and implementation research can access funding through the National Institutes of Health. NIH provides support for Laboratory Centers that manage clinical trial lab infrastructure, testing, data systems, and advanced assays within HIV/AIDS Clinical Trials Networks across the U.S. and territories.

Research institutions and clinical trial networks working on HIV/AIDS prevention, treatment, and implementation research in Montana and nationwide can apply for NIH support to lead a Clinical Trials Network Leadership and Operations Center. US Dept. of Health & Human Services: National Institutes of Health funds LOCs focused on therapeutics, biomedical prevention, immune-based strategies, and maternal, adolescent, and pediatric HIV care.

Montana research institutions working on substance use, addiction, and HIV can access funding through the National Institutes of Health to establish a NIDA Core Center of Transformative Science. These centers support shared research resources, interdisciplinary collaboration, and opportunities for early-career investigators across existing federally or non-federally funded projects.

U.S.-based research organizations working on HIV/AIDS can apply for National Institutes of Health awards of US $212,004 - US $2,725,311 to develop and manage specific pathogen free in vivo models and human new approach methodologies. This opportunity may benefit Montana investigators advancing HIV research resources and in vitro testing capabilities.

The National Institute of Mental Health is inviting research applications for the AIDS Research Center program, which includes Developmental Centers and full Research Centers. This initiative aims to enhance interdisciplinary HIV/AIDS research through collaboration and innovative approaches across various scientific domains. The program emphasizes alignment with national strategies and encourages applications from teams skilled in fostering partnerships with diverse stakeholders. Although applications are currently not being solicited, this notice allows potential applicants time to prepare strong proposals.

The Ryan White HIV/AIDS Program (RWHAP) Integrated HIV/AIDS Planning Resource Allocation Cooperative Agreement aims to enhance the effectiveness of HIV prevention and care planning for RWHAP Parts A and B recipients. Through the provision of training, tools, and technical assistance, this initiative seeks to optimize resource allocation and strengthen the overall system of HIV care and treatment, ultimately improving health outcomes for those affected by HIV.

The AIDS Drug Assistance Program (ADAP) Emergency Relief Funds aim to provide essential funding to states and territories. This initiative focuses on preventing, reducing, or eliminating waiting lists for ADAP services, ensuring timely access to necessary medications and support for individuals living with HIV/AIDS. This program addresses critical funding shortfalls, enhancing the healthcare infrastructure and improving health outcomes in affected communities.

The Ryan White HIV/AIDS Program Part C Capacity Development Program aims to enhance the capabilities of community-based organizations, focusing on improving health outcomes and decreasing HIV transmission. This initiative supports individuals who have not yet accessed regular HIV care, emphasizing innovative care solutions and infrastructure development to address these critical needs.

The HIV Care Grant Program, funded by the US HHS: Health Resources & Services Administration (HRSA), aims to enhance access to high-quality HIV care and treatment for low-income individuals. This initiative supports states and territories in developing comprehensive systems to address the needs of those living with HIV. By providing essential resources, the program seeks to improve health outcomes and ensure that vulnerable populations receive the necessary support and services.

The Ryan White HIV/AIDS Program Part B Supplemental Grant aims to provide essential funding to support HIV care and treatment services across states and territories. This program supplements existing formula-based funding from the RWHAP Part B and ADAP, improving access to necessary resources for those affected by HIV/AIDS. By enhancing support structures, it addresses critical healthcare needs, ensuring better health outcomes for vulnerable populations.

The HIV Care Grant Program aims to enhance access to comprehensive, high-quality HIV care and treatment for low-income individuals in Pacific Island territories. Funded by the US HHS: Health Resources & Services Administration (HRSA), this initiative supports states and territories in developing effective systems of care, ensuring that those affected by HIV receive the necessary treatment and support to improve health outcomes.

This funding opportunity aims to enhance a web-based ordering portal for distributing 1.5 million HIV and STI self-tests to high-burden communities. By optimizing access to these self-tests, the initiative seeks to raise awareness, prevent new infections, and improve the health outcomes of users, thereby contributing to better overall public health and wellbeing.

This project aims to enhance health outcomes for women living with HIV in the South by integrating HIV care with comprehensive women's health services through coordinated Clinic and Community Collaboratives. By funding organizations to implement targeted strategies such as culturally responsive services and learning collaboratives, the initiative seeks to improve access to essential health services, increase the number of women initiating rapid ART, and foster sustainable healthcare models that address the unique needs of this population.

The Ryan White HIV/AIDS Program Part D provides supplemental funding aimed at enhancing the infrastructure and capacity of organizations to deliver high-quality, family-centered HIV care services. This initiative focuses on two key areas: HIV Care Innovation and Infrastructure Development, ensuring improved access to essential services for women, infants, children, and youth affected by HIV.

The Ryan White HIV/AIDS Program Part B AIDS Drug Assistance Program Training and Technical Assistance aims to enhance the capacity of ADAPs. By providing essential tools and expert guidance, the program seeks to improve health outcomes for individuals living with HIV in an evolving healthcare landscape. This initiative is funded by the US HHS through the Health Resources & Services Administration, ensuring support and resources are effectively allocated to meet the needs of vulnerable populations.

Gilead Sciences

At Gilead, we are relentlessly committed to advancing transformative therapies for the most serious diseases, delivering an exponentially positive impact on health.

For more than three decades, we have combined scientific rigor with a deep sense of purpose to improve health outcomes and reimagine care. Our work spans more than 35 countries with a focus on three therapeutic areas: virology, oncology, and inflammation, where unmet medical needs remain greatest.

From individual patients to whole populations, we’re committed to delivering healthier futures for people and communities worldwide.

Our Mission: To discover, develop and deliver innovative therapeutics for people with life-threatening diseases.

HIV Prevention NOVA 2026

Program Description

Gilead Sciences invites research proposals that advance the evidence base for innovative and scalable models of delivery for long-acting (LA) HIV pre-exposure prophylaxis (PrEP) in the United States.

This Topic of Interest (TOI) is focused on care delivery models implemented in non-traditional settings, defined as clinical and non-clinical environments where PrEP services are not routinely provided. Emphasis is placed on approaches that reflect real-life practice and address gaps in current PrEP delivery infrastructure.

Persistent inequities in PrEP uptake in the U.S. suggest that expanding availability within traditional clinical settings alone is unlikely to reach all populations with unmet PrEP need.1,2 Rigorous implementation studies in non-traditional settings where PrEP services are not routinely provided are needed to evaluate whether these models can reduce access barriers and improve equitable reach among individuals who may benefit from PrEP.2,3,4

The goal of this TOI is to generate practical, decision-relevant evidence that informs how LA PrEP can be implemented, scaled, and sustained in real-life U.S. settings.

About Patient Advocate Foundation

Patient Advocate Foundation is the nation’s most comprehensive nonprofit dedicated to helping patients navigate, access, and afford the care they need—while improving the healthcare system for all.

Who we are and our impact

Patient Advocate Foundation provides financial assistance to help patients afford treatment and cost of living needs, personalized case management to navigate complex healthcare and social needs challenges, and a wide array of resources to empower people to take charge of their health. Since our founding in 1996—and joining forces with the PAN Foundation in 2026—we have helped 3.8 million patients navigate and access care, granted over $7 billion in financial assistance, served 350,000 people through personalized case management and elevated the patient’s voice to drive improvements in the healthcare system.

HIV, AIDS, and prevention

Help with healthcare costs for HIV, AIDS, and prevention

This TotalAssist fund helps you pay for out-of-pocket healthcare costs, including medication copays, coinsurance, and deductibles, health insurance premiums, and other expenses.

About the disease

HIV, also known as human immunodeficiency virus or acquired immunodeficiency syndrome, is a virus that attacks the immune system. When left untreated, it can develop into AIDS. HIV is a chronic disease that affects the immune system.

The SCORCH Program: Phase 2 aims to enhance the understanding of single cell biology in the context of HIV and Substance Use Disorder (SUD). Building on previous research, this initiative will explore new single cell approaches to investigate the interactions between SUD and HIV progression at various biological levels. By leveraging advanced techniques, the program seeks to identify candidate mechanisms and potential therapeutic targets, ultimately contributing to innovative solutions for SUDs and HIV-related challenges.

Bristol Myers Squibb is dedicated to enhancing healthcare and advancing scientific knowledge through its Corporate Giving program. By supporting various organizations, BMS aims to improve health equity and access to essential medicines for underserved populations. Their focus includes charitable donations, medical education, and community support initiatives. This commitment reflects BMS's goal to make a positive impact on patients' lives and foster strong communities where their employees work and live.

The Elizabeth Taylor AIDS Foundation (ETAF) provides grants focused on HIV/AIDS care, advocacy, and education. Grants are awarded annually based on a review process, emphasizing projects that align with Ms. Taylor’s vision. Eligible organizations must have at least three years of experience in HIV/AIDS programs and can apply only once per year. ETAF prioritizes funding for direct care and prevention initiatives, while restricting support for multi-year proposals and non-HIV specific projects.